Management of limited stage DLBCL without bulky disease

This algorithm should be used together with related UpToDate topics for diagnosis, staging, management, and follow-up of DLBCL. We consider bulky disease to be a tumor mass ≥10 cm in diameter; PET-negative (Deauville 1-3); and PET-positive (Deauville 4-5).

DLBCL: diffuse large B cell lymphoma; LDH: lactate dehydrogenase; ECOG PS: Eastern Cooperative Oncology Group Performance Status; R-CHOP: rituximab, cyclophsophamide, vincristine, doxorubicin, prednisone; PET3: positron emission tomography after 3 cycles of R-CHOP; ISRT: involved site radiation therapy; Gy: gray; FDG: fluorodeoxyglucose.
* Some experts add two additional treatments of rituximab, alone.

Graphic 127165 Version 1.0

خرید پکیج

Management of limited stage DLBCL without bulky disease